Compare · NVO vs VTVT
NVO vs VTVT
Side-by-side comparison of Novo Nordisk A/S (NVO) and vTv Therapeutics Inc. (VTVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and VTVT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 1551.2x VTVT ($108.8M).
- VTVT has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 6 for VTVT).
- Company
- Novo Nordisk A/S
- vTv Therapeutics Inc.
- Price
- $38.76-1.20%
- $27.66+0.24%
- Market cap
- $168.79B
- $108.8M
- 1M return
- -10.29%
- -
- 1Y return
- -30.89%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 4
- 7
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest VTVT
- iOnctura appoints Paul Sekhri as Chair of its Board of Directors
- vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by vTv Therapeutics Inc.
- vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
- SEC Form 8-K filed by vTv Therapeutics Inc.
- vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
- vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
- vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- vTv Therapeutics to Participate in September Investor Conferences
- vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)